BEIJING, May 6, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that Mr. Sam Tsang, the Company's Chief Financial Officer will present at Jefferies 2011 Global Healthcare Conference in New York at 12:45pm on June 7, 2011 and will meet institutional investors at the conference throughout the date. He will travel to Boston, Chicago and Los Angeles to meet institutional investors during the rest of the week. Mr. David Chung, the Company's Financial Controller and Ms. Winnie Yam, the Company's Investor Relations Manager will participate in Bank of America Merrill Lynch HK China Healthcare Corporate Day in Hong Kong on June 8, 2011.
About China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.ContactWinnie YamTel: 852-2511-9808Email: IR@chinameditech.com
|SOURCE China Medical Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved